iBio Inc, a biotechnology company, has been the subject of a Schedule 13G filing with the U.S. Securities and Exchange Commission (SEC), indicating a significant acquisition of shares by Ikarian Capital, LLC and Neil Shahrestani. The filing, dated September 30, 2024, and disclosed on November 14, 2024, reports that Ikarian Capital and Shahrestani collectively hold 599,913 shares of iBio Inc's common stock, representing 6.6% of the company's total shares outstanding as of November 12, 2024. Ikarian Capital, a Delaware-based investment adviser, manages these shares through the Ikarian Healthcare Master Fund, L.P., and certain separately managed accounts. Neil Shahrestani, who has indirect control over Ikarian Capital, is also reported as a beneficial owner of the shares. The filing emphasizes that this acquisition does not aim to change or influence the control of iBio Inc.

iBio Inc, a biotechnology company, has been the subject of a Schedule 13G filing with the U.S. Securities and Exchange Commission (SEC), indicating a significant acquisition of shares by Ikarian Capital, LLC and Neil Shahrestani. The filing, dated September 30, 2024, and disclosed on November 14, 2024, reports that Ikarian Capital and Shahrestani collectively hold 599,913 shares of iBio Inc's common stock, representing 6.6% of the company's total shares outstanding as of November 12, 2024. Ikarian Capital, a Delaware-based investment adviser, manages these shares through the Ikarian Healthcare Master Fund, L.P., and certain separately managed accounts. Neil Shahrestani, who has indirect control over Ikarian Capital, is also reported as a beneficial owner of the shares. The filing emphasizes that this acquisition does not aim to change or influence the control of iBio Inc.